N-Glycolyl Muramyl Dipeptide elicits Cellular Immunity of Complete Freund's Adjuvant

N-甘醇胞壁酰二肽引发弗氏完全佐剂的细胞免疫

• 批准号: 350056
• 负责人: Dube Jean-Yves
• 金额: $ 1.27万
• 依托单位: McGill University
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2015
• 资助国家: 加拿大
• 起止时间: 2015-12-01 至 2016-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=350056&lang=en
• 关键词: Adjuvancy; Cell-Mediated Immunity (Cmi); Freund'S Adjuvant; Muramyl Dipeptide; Mycobacteria; Mycobacterium Tuberculosis; N-Glycolyl Muramyl Dipeptide; Nucleotide-Binding Oligomerization Domain Containing (Nod) 2; Peptidoglycan; Vaccination

The immune system uses antibodies and cells to protect the body. Most vaccines used today induce antibodies to block extracellular infectious agents. However, vaccines that produce cell-mediated immunity (CMI) are still critically needed to prevent intra

免疫系统使用抗体和细胞来保护身体。今天使用的大多数疫苗都会诱导抗体来阻断细胞外的感染性病原体。然而，产生细胞免疫(CMI)的疫苗仍然是预防体内感染的关键。